Table 7.
Analysis of APEX2 modifiable amino acid targets of various Inc proteins
| Inc protein Serovar D naming convention |
Targets (#a) |
Length (AAb) |
modifiable residuesc (%) |
|---|---|---|---|
| CT101d | 18 | 153 | 11.76 |
| CT249 | 9 | 116 | 7.76 |
| CT058 | 25 | 367 | 6.81 |
| CT222d | 8 | 128 | 6.25 |
| IncE | 7 | 132 | 5.3 |
| CT223d | 14 | 268 | 5.22 |
| IncBd | 6 | 115 | 5.22 |
| CT850d | 21 | 405 | 5.19 |
| CT813 | 13 | 264 | 4.92 |
| CT005 | 16 | 363 | 4.41 |
| IncD | 6 | 146 | 4.11 |
| IncA | 11 | 273 | 4.03 |
| IncF | 4 | 104 | 3.85 |
| IncG | 6 | 167 | 3.59 |
| CT226 | 6 | 176 | 3.41 |
| CT228 | 6 | 196 | 3.06 |
a
number of amino acid targets for APEX2
b
amino acid (AA)
c
number of AA targets divided by Inc length
d
endogenous protein localizes in microdomains